Comprehensive Genomic Profiling (CGP) in the U.S. - Head of Translational Research, Top 20 Pharma

A head of translational research at a major pharma company views CGP as a crucial component of personalized medicine and described its importance in driving clinical decision-making and making actionable recommendations for physicians. They believe that CGP should involve whole exome profiling and encompass all common variant types. The stakeholder benchmarks several major players as the gold standard in CGP and discusses their organization's current use of CGP in generating vaccines and analyzing treatment response patterns in clinical trials. They mention that there may be a shift towards in-house testing in the long term, depending on the specific use case and economics. The stakeholder also highlights several technical limitations in achieving comprehensive coverage and mentions pain points associated with CGP testing, including the complexity of bioinformatics analysis. Overall, the stakeholder's perception of CGP is positive, considering it essential for personalized medicine and highlighting the need for CGP vendors that excel in execution and clinical reporting.

‍